Cleara is developing peptide-based therapeutics that selectively eliminate "scarred" senescent cells associated with chronic diseases and late-stage cancers, utilizing a proprietary platform technology to target specific cellular pathways. Their lead candidates, CL04177 and CL04183, demonstrate effective clearance of these cells in preclinical models, aiming to advance precision medicine for metastatic colon and triple-negative breast cancers.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Senescent cells, particularly "scarred" senescent cells, contribute to chronic diseases and the progression of late-stage cancers, such as metastatic colon cancer and triple-negative breast cancer. Current therapeutic approaches often lack the specificity needed to target these detrimental senescent cell subtypes without harming healthy cells. This lack of precision limits the efficacy and increases the potential toxicity of treatments.
Solution
Cleara Biotech is developing peptide-based therapeutics designed to selectively eliminate "scarred" senescent cells, a specific subtype of senescent cells associated with chronic diseases and late-stage cancers. The company's proprietary platform identifies and targets unique molecular pathways within these cells, enabling the design of therapeutics that exploit their vulnerabilities for safe and selective clearance. Cleara's lead compounds, CL04177 and CL04183, exhibit favorable pharmacokinetics, tissue distribution, and plasma stability, demonstrating potent anti-metastatic activity in preclinical models of metastatic colon cancer and triple-negative breast cancer. These compounds are designed to overcome the limitations of existing therapies by precisely targeting the detrimental senescent cells while sparing healthy cells.
Target Audience
The primary target audience includes patients with metastatic colon cancer, triple-negative breast cancer, and other chronic diseases associated with "scarred" senescent cells, as well as pharmaceutical companies seeking novel therapeutics for these conditions.
Features
- Peptide-based therapeutics that selectively eliminate "scarred" senescent cells.
- Proprietary platform technology for identifying and targeting specific molecular pathways in senescent cells.
- Lead compounds CL04177 and CL04183 demonstrate efficacy in preclinical models of metastatic colon cancer and triple-negative breast cancer.
- Compounds exhibit favorable pharmacokinetics, tissue distribution, and plasma stability.
- Designed with D-amino acids for resistance to degradation by liver enzymes and extended shelf-life.
- Preclinical and clinical development strategy incorporates associated biomarkers for precision medicine.